Cullinan Oncology
CGEM
145 hedge funds and large institutions have $362M invested in Cullinan Oncology in 2025 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 56 increasing their positions, 37 reducing their positions, and 26 closing their positions.
51% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 37
1% more funds holding
Funds holding: 143 → 145 (+2)
8% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 26
2.7% less ownership
Funds ownership: 106.09% → 103.39% (-2.7%)
23% less capital invested
Capital invested by funds: $471M → $362M (-$109M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
38% less call options, than puts
Call options by funds: $175K | Put options by funds: $280K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$10M |
| 2 |
Goldman Sachs
New York
|
+$2.06M |
| 3 |
Jane Street
New York
|
+$1.85M |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$1.63M |
| 5 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$1.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$6.8M |
| 2 |
PSC
Patient Square Capital
Menlo Park,
California
|
-$6.54M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$5.95M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$5.03M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$4.61M |
CGEM Hedge Fund Activity: Q3 2025 in Review
145 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Cullinan Oncology (CGEM) for Q3 2025, worth a combined $362M — down 23% from $471M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new CGEM positions and 26 closed out — a net gain of 2 holders — while 56 added to existing stakes and 37 trimmed.
The largest buyer was Lynx1 Capital Management, adding an estimated $10M. The largest seller was Deerfield Management, cutting an estimated $6.8M.
- 145 institutional investors held Cullinan Oncology (CGEM) as of Q3 2025, up from 143 in Q2 2025.
- Funds reported $362M of Cullinan Oncology stock for Q3 2025, down 23% quarter-over-quarter.
- 28 funds opened new Cullinan Oncology positions in Q3 2025 and 26 closed out, a net change of +2 holders.
- The largest Cullinan Oncology buyer in Q3 2025 was Lynx1 Capital Management, an estimated $10M added.
- The largest Cullinan Oncology seller in Q3 2025 was Deerfield Management, an estimated $6.8M sold.
Based on aggregated 13F filings for Q3 2025.